Maximilian Stahl, MD
Assistant ProfessorCards
About
Titles
Assistant Professor
Director Leukemia and Myeloid Malignancy Program, Yale Cancer Center; Chief Duffy Hematology Firm, Yale-New Haven Hospital
Biography
Maximilian Stahl, MD, is the Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, Chief of the Duffy Hematology Firm at Yale-New Haven Hospital and an Assistant Professor of Medicine (Medical Oncology and Hematology) at Yale University School Of Medicine.
He cares for patients with hematologic malignancies at Smilow Cancer Hospital in New Haven with a particular focus on acute and chronic leukemias and myelodysplastic syndromes. Dr. Stahl joined Yale from Dana-Farber Cancer Institute and Harvard Medical School where he was an Assistant Professor of Medicine within the Adult Leukemia Program.
Dr. Stahl received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where he also served as chief medical resident. He then completed a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, where he also served as chief fellow, and a postdoctoral research fellowship at Rockefeller University.
His clinical research evaluates outcomes achieved with novel therapeutic approaches for AML, MDS, and MPNs, with a focus on identifying molecular predictors of these outcomes. Dr. Stahl actively leads clinical and translational research with the goal of bringing basic scientific discoveries from the lab to the clinic to benefit patients with leukemia. Towards this goal, he conducts early phase clinical trials testing novel treatment approaches. Dr. Stahl is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for MDS and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) focusing on early phase clinical trials of novel therapies for myeloid malignancies.
Dr. Stahl authored and co-authored more than 130 peer reviewed publications and has presented his research in multiple national and international meetings. He has received the ASCO Conquer Cancer Foundation Young Investigator Award, the ASH HONORS Award, the Leukemia & Lymphoma Society Translational Research Program Award and several ASH Abstract Achievement Awards. He is a member of the Editorial Board of Leukemia & Lymphoma and serves as an ad hoc reviewer for several journals including Blood, Blood Advances, Leukemia, Clinical Cancer Research, the British Journal of Haematology and Haematologica. He is also also a member of the National Comprehensive Cancer Network Clinical Practice Panel for AML and MDS.
Departments & Organizations
Education & Training
- Clinical Fellow
- Memorial-Sloan Kettering Cancer Center (2021)
- Research Fellow
- The Rockefeller University (2021)
- Chief Resident
- Yale School of Medicine (2018)
- Resident
- Yale School of Medicine (2017)
- Intern
- Yale School of Medicine (2015)
- Post-doctoral Fellow
- Yale University (2014)
- MD
- Hannover Medical School (2013)
Research
Overview
My research is focused on evaluating the safety and efficacy of novel therapeutic approaches for myeloid malignancies especially acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). As a clinical investigator, I focus on developing investigator-initiated early phase clinical trials for patients with myeloid malignancies.
Medical Research Interests
Public Health Interests
Academic Achievements & Community Involvement
Clinical Care
Overview
Maximilian Stahl, MD, is an internist specializing in hematology and oncology, with a focus on leukemia and other myeloid malignancies. He provides comprehensive care for patients with acute and chronic leukemias, myelodysplastic syndromes, and related blood disorders.
Dr. Stahl believes in open communication and being transparent with patients about their disease and treatment options. “I want my patients to feel free to ask me a lot of questions,” he says. “I believe that by understanding their disease better, a lot of a patient’s fear surrounding their cancer diagnosis can often be reduced. I also welcome family members to join the visits with me, as I understand that cancer often affects the entire family. While we cannot always promise a positive outcome, my entire team and I will work very hard to give patients the best treatment available.”
As an assistant professor of medicine at Yale School of Medicine and director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, Dr. Stahl leads research into innovative therapies for blood cancers. He conducts clinical trials investigating new treatment approaches and uses molecular studies to better predict patient outcomes and is active in national initiatives such as the National Cancer Institute’s MyeloMATCH Precision Medicine Initiative.
Dr. Stahl became drawn to the field of oncology when his grandfather was diagnosed with cancer. “There were few treatment options available,” he shares. "Improving therapies for patients with cancer in the future was the major motivation for me to pursue a career in oncology. My goal is to develop novel and better therapies for patients diagnosed with leukemia and other myeloid neoplasms who have currently no adequate standard of care options available to them. I hope that by the time I retire, we will be able to cure all patients affected by leukemia.”
Dr. Stahl received his medical degree from Hannover Medical School in Germany, completed residency training at Yale School of Medicine, and pursued fellowship training in hematology and medical oncology at Memorial Sloan Kettering Cancer Center where he also served as chief resident. He subsequently pursued fellowship training in hematology and medical oncology at Memorial Sloan Kettering Cancer Center.
Clinical Specialties
Board Certifications
Hematology (Internal Medicine)
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2021
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2017
News
News
- May 01, 2025
Dr. Maximilian Stahl Receives DeLuca Center for Innovation in Hematology Career Development Award
- April 01, 2025
Hematologist, Dr. Maximilian Stahl, Joins Smilow Cancer Hospital
- March 19, 2018Source: Healio
Pacritinib reduces splenomegaly, symptoms in myelofibrosis
- December 09, 2017Source: Healio
Immunosuppressive therapy leads to transfusion independence for nearly 40% of patients with myelodysplastic syndrome
Get In Touch
Contacts
Yale Cancer Center
37 College Street
New Haven, Connecticut 06510
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Everyone Amer Zeidan, MBBS - Ted Getz, MD - Lourdes Mendez, MD, PhD - Maximilian Stahl, MD - Cristian Taborda, MD